{"id":14471,"date":"2012-01-19T10:32:00","date_gmt":"2012-01-19T09:32:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/le-pagelle-dei-pazienti-a-big-pharma\/"},"modified":"2012-01-19T10:32:00","modified_gmt":"2012-01-19T09:32:00","slug":"le-pagelle-dei-pazienti-a-big-pharma","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/le-pagelle-dei-pazienti-a-big-pharma\/","title":{"rendered":"Patient report cards at Big Pharma"},"content":{"rendered":"

The 42% of patient associations thinks that, in general, multinational drug companies have a "good" or "excellent" reputation. This was revealed by a survey conducted by PatientView among the 500 main and most influential patient associations in 61 countries around the world. <\/p>\n

<\/font><\/font><\/span><\/p>\n

Swiss Novartis gets the best evaluation, with the highest score in 4 of the 6 indicators evaluated among 30 drug companies: whether or not they have an effective patient-oriented strategy; the quality of the information provided to patients; the interest in the safety of the latter; the usefulness of the products to patients. Gilead was rated best on the other two indicators: focus on transparency with external stakeholders and conducting business with integrity. <\/p>\n

<\/font><\/font><\/span><\/p>\n

Factors in which Novartis ranked second and third, respectively. The industries involved were Abbott, Actavis, Allergan, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Genzyme, Gilead, GlaxoSmithKline, Johnson & Johnson, Lundbeck, Merck &Co and Msd, Merck KGaA, Novartis, Novo Nordisk, Nycomed, Pfizer, Ro che, Sanofi, Servier, Shire, Takeda, Teva and Ucb. <\/p>\n

<\/font><\/font><\/span><\/p>\n

Pfizer and Lundbeck rank second and third in global reputation, which PatientView defines as "ability to meet the expectations of patients and their associations." A reputation that all in all does not seem to be the best: only the 42% of patient associations believe that drug multinationals have a "good" or "excellent" reputation, with percentages rising to 44 and 41% for the biotech and generics industries.<\/p>\n

<\/font><\/font><\/span><\/p>\n

Therefore less than the 62% reached by pharmacists, the 54% of private health insurers and the 53% of medical device companies. Only a minority of respondents also think that Big Pharma's reputation has improved over the past five years, with 38% considering it to have declined and 33% calling it unchanged. And while 66% of those interviewed believe that the level of innovation of pharmaceutical companies is "good" or "excellent", only 13% says that companies adopt effective strategies of fair pricing, which avoid unfair profits. <\/p>\n

<\/font><\/font><\/span><\/p>\n

Il 42% delle associazioni di pazienti pensa che, in generale, le multinazionali del farmaco abbiano una "buona" o "eccellente" reputazione. Lo rivela un’indagine condotta da PatientView fra le 500 principali e più influenti associazioni di malati in 61 Paesi di tutto il mondo. La svizzera Novartis ottiene la migliore valutazione, con il punteggio più alto …<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-14471","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/14471","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=14471"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/14471\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=14471"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=14471"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=14471"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}